Arrowhead Pharma Files 8-K/A Amendment
Ticker: ARWR · Form: 8-K/A · Filed: Mar 18, 2024 · CIK: 879407
Sentiment: neutral
Topics: corporate-governance, amendment, officer-changes, director-changes
Related Tickers: ARWR
TL;DR
Arrowhead Pharma amended its 8-K filing regarding exec/director changes and compensation.
AI Summary
Arrowhead Pharmaceuticals, Inc. filed an 8-K/A amendment on March 18, 2024, related to events that occurred on February 21, 2024. The filing concerns the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements for certain officers.
Why It Matters
This amended filing provides updated information regarding changes in Arrowhead's executive and director positions, which can impact company leadership and strategic direction.
Risk Assessment
Risk Level: low — The filing is an amendment to a previous report and concerns corporate governance matters, not immediate financial distress or significant operational shifts.
Key Players & Entities
- Arrowhead Pharmaceuticals, Inc. (company) — Registrant
- Delaware (jurisdiction) — State of incorporation
- February 21, 2024 (date) — Earliest event date
- March 18, 2024 (date) — Filing date
FAQ
What specific event prompted the original 8-K filing that is now being amended?
The filing does not specify the exact event that prompted the original 8-K, but it is an amendment related to the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements.
What is the significance of the '8-K/A' filing type?
An 8-K/A is an amendment to a previously filed 8-K report, indicating that the company is correcting or adding information to its original filing.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on February 21, 2024.
What is the principal executive office address for Arrowhead Pharmaceuticals, Inc.?
The principal executive office is located at 177 E. Colorado Blvd, Suite 700, Pasadena, CA 91105.
What are the main topics covered by this 8-K/A filing?
The filing covers the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers.
Filing Stats: 676 words · 3 min read · ~2 pages · Grade level 11.2 · Accepted 2024-03-15 19:21:25
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share ARWR The Nasdaq Global Select
- $761,666 — ant of restricted stock units valued at $761,666. These restricted stock units are sched
Filing Documents
- arwr-20240221.htm (8-K/A) — 29KB
- 0001628280-24-011557.txt ( ) — 153KB
- arwr-20240221.xsd (EX-101.SCH) — 2KB
- arwr-20240221_lab.xml (EX-101.LAB) — 22KB
- arwr-20240221_pre.xml (EX-101.PRE) — 13KB
- arwr-20240221_htm.xml (XML) — 3KB
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Date: March 18, 2024 ARROWHEAD PHARMACEUTICALS, INC. By: /s/ Kenneth Myszkowski Kenneth Myszkowski Chief Financial Officer